Latest News

Filters

Filter by tags: Europe Iodine-131 Clear all tag filters

7 news articles found


Russia's Ministry of Industry and Trade, representatives from the Kaluga region and the city of Obninsk, and Rosatom have signed a special investment contract for the construction of what Rosatom says will be Europe's largest plant for the production of radiopharmaceuticals.

Date: Wednesday, 11 October 2023
Original article: world-nuclear-news.org/Articles/Special-investment-contract-signed-for-Russian-med

International Atomic Energy Agency (IAEA) Director General Rafael Mariano Grossi says IAEA experts present at Ukraine’s Zaporizhia NPP (ZNPP) have in recent days and weeks inspected parts of the facility – including some sections of the perimeter of the large cooling pond – and have also conducted regular walkdowns across the site, so far without observing any visible indications of mines or explosives.

Date: Friday, 07 July 2023
Original article: neimagazine.com/news/newsattack-on-zaporizhia-npp-may-have-been-averted-10988247

Advances in emerging field of ‘theranostics’ are a game-changer Millions of patients around the globe rely on the regular and timely production of diagnostic and therapeutic isotopes produced in research reactors and accelerator facilities. Image courtesy IAEA. Advances in medical isotope diagnostics and therapy are holding promise for cancer patients, despite challenges facing the nuclear medical field in recent years related to radionuclide production and supply, rising costs, and stricter regulation.

Medical isotopes are radioactive substances used in various diagnostic and therapeutic procedures to treat various types of cancers and other conditions. They are essential for modern medicine, allowing physicians to visualise and target specific organs, tissues and cells in a patient’s body.

Over more than a decade, personalised medicine using nuclear techniques has been gaining pace, allowing doctors to tailor therapies and treatments to the specific needs and physiology of a patient, and to avoid harm to healthy organs or tissues.

According to Sven Van den Berghe, chief executive of Belgium-based isotope producer PanTera, one technique that has seen significant advances is known as theranostics – the term used to describe the combination of using one radioactive drug to diagnose and a second to deliver therapy to treat the main tumour and any metastatic tumours.

Date: Friday, 14 April 2023
Original article: nucnet.org/news/sector-aims-to-tackle-isotope-supply-problems-as-excitement-grows-over-targeted-therapies-4-4-2023

Rosatom has begun construction of a new plant for the production of medical isotope products at the Karpov Scientific Research Institute of Physics & Chemistry in Obninsk, Kaluga region. The plant will produce a wide range of radiopharmaceuticals including those based on iodine-131, samarium-153, and molybdenum-99 isotopes. It will also develop promising active radiopharmaceuticals based on lutetium-177, actinium-225, radium-223 and other isotopes. Once completed, in 2025, it will be the largest such facility in Europe, Rosatom says. It will operate in accordance with international GMP (good manufacturing practice) standards.

Date: Friday, 27 January 2023
Original article: neimagazine.com/news/newsrosatom-begins-construction-of-radiopharmaceuticals-plant-10546229

The aim is to have production lines operating at the plant in Obninsk by 2025, supplying products for the diagnosis and treatment of patients, including a wide range of cancers. Rosatom says it will ensure Russia's sovereignty in the production of radiopharmaceuticals.

Date: Wednesday, 25 January 2023
Original article: world-nuclear-news.org/Articles/Construction-starts-for-Russian-medical-isotopes-p

SHINE Technologies of the USA has announced its European subsidiary, SHINE Europe, has secured funding to begin designing an advanced medical isotope production facility at Veendam in the Netherlands.

Date: Thursday, 03 February 2022
Original article: world-nuclear-news.org/Articles/Financing-in-place-for-European-SHINE-isotope-plan

The supply of Russian radioisotope products to Brazil has allowed the Brazilian government to reduce by half the costs of inputs that help diagnose and treat various cancers, according to Jair Mengatti, production director of Brazil's Institute of Energy and Nuclear Research (IPEN). Over the past years, IPEN, the main producer of radiopharmaceuticals in Brazil, has had problems getting inputs such as Iodine-131, now 100% imported from Russia. "Up until the end of last year, our supplier was from Canada, but after the bidding process, we went to Russia for our supplies. We saved around $100,000 a week," he said.

Date: Wednesday, 22 June 2016
Original article: neimagazine.com/news/newsrussia-looks-to-expand-global-radioisotope-supplies-4930195